Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Euro Surveill ; 19(40): 20921, 2014 Oct 09.
Article in English | MEDLINE | ID: mdl-25323077

ABSTRACT

We reviewed the epidemiology of pertussis in Italy over the last 125 years to identify disease trends and factors that could have influenced these trends. We described mortality rates (1888-2012), case fatality rates (1925-2012), cumulative incidence rates (1925-2013) and age-specific incidence rates (1974-2013). We compared data from routine surveillance with data from a paediatric sentinel surveillance system to estimate under-notification. Pertussis mortality decreased from 42.5 per 100,000 population in 1890 to no reported pertussis-related death after 2002. Incidence decreased from 86.3 per 100,000 in 1927 to 1 per 100,000 after 2008. Vaccine coverage increased from 32.8% in 1993 to about 96% after 2006. As for under-notification, mean sentinel/routine surveillance incidence ratio increased with age (from 1.8 in <1 year-olds to 12.9 in 10-14 year-olds). Pertussis mortality decreased before the introduction of immunisation. Incidence has decreased only after the introduction of pertussis vaccine and in particular after the achievement of a high immunisation coverage with acellular vaccines. Routine surveillance does not show an increase in cumulative incidence nor in ≥ 15 year-olds as reported by other countries. Underrecognition because of atypical presentation and the infrequent use of laboratory tests may be responsible for under-notification, and therefore affect incidence reports and management of immunisation programmes.


Subject(s)
Mortality/trends , Pertussis Vaccine/administration & dosage , Whooping Cough/epidemiology , Adolescent , Adult , Age Distribution , Aged , Bordetella pertussis , Child , Child, Preschool , Female , History, 19th Century , History, 20th Century , History, 21st Century , Humans , Immunization Programs/history , Incidence , Infant , Italy/epidemiology , Male , Middle Aged , Pertussis Vaccine/history , Sentinel Surveillance , Whooping Cough/history
2.
J Econ Entomol ; 106(4): 1574-81, 2013 Aug.
Article in English | MEDLINE | ID: mdl-24020268

ABSTRACT

"Corn stunt" is one of the main corn (Zea mays L.) diseases in the Americas and Dalbulus maidis (DeLong & Wolcott) is the key vector of the pathogen Spiroplasma kunkelii Whitcomb. In Argentina, the corn-producing area is in the temperate region, where vector and pathogen prevalence levels are unknown. In this study, the prevalence and distribution of D. maidis and S. kunkelii in the temperate region of Argentina and D. maidis overwintering ability in this region were determined. Surveys were conducted in 2005-2006 and 2006-2007 seasons to determine D. maidis and S. kunkelii presence, and in winter 2006 to determine the vector overwintering ability. The highest S. kunkelii prevalence and incidence levels were found in the transition area from the temperate to the subtropical region, related to the highest D. maidis prevalence and insects sampled per location. D. maidis adults were found in volunteer corn plants and spontaneous vegetation in autumn and winter months, which were inoculative for the pathogen S. kunkelii. This overwintering ability was related to detection of D. maidis insects in corn crops at early growth stages in the following growing season. This work emphasizes that corn stunt disease is present in the temperate region of Argentina, and this highlights the need to develop proper agronomic practices like monitoring insect vector populations and controlling voluntary plants. This study also indicates that further research is needed to understand the potential yield reduction caused by this pathogen on symptomless plants and population dynamics of the insect vector.


Subject(s)
Hemiptera/microbiology , Hemiptera/physiology , Plant Diseases/microbiology , Spiroplasma/physiology , Zea mays/microbiology , Animals , Argentina , Seasons , Zea mays/growth & development
3.
Vaccine ; 30(34): 5172-8, 2012 Jul 20.
Article in English | MEDLINE | ID: mdl-21414380

ABSTRACT

Since children with chronic diseases represent a primary target for immunization strategies, it is important that their immunization coverage and timeliness of vaccines is optimal. We performed a study to measure immunization coverage and timeliness of vaccines in children with type 1 diabetes, HIV infection, Down syndrome, cystic fibrosis, and neurological diseases. A total of 275 children aged 6 months-18 years were included in the study. Coverage for diphtheria-tetanus-pertussis (DTP), polio (Pol), and hepatitis B (HBV) vaccines approximated 85% at 24 months, while measles-mumps-rubella (MMR) coverage was 62%. Immunization coverage for seasonal influenza was 59%. The analysis of timeliness revealed that there was heterogeneity among children with different chronic diseases. A proportional hazard model showed that children with HIV infection had the longest time to complete three doses of DTP, Pol, and HBV, and those with neurological diseases received the first dose of MMR later than the other categories. Causes of missing or delayed vaccination mostly included a concurrent acute disease. Children with chronic diseases should be strictly monitored for routine and recommended vaccinations, and health care providers and families should be properly informed to avoid false contraindications.


Subject(s)
Chronic Disease/prevention & control , Immunization Programs/statistics & numerical data , Immunization Schedule , Vaccination/statistics & numerical data , Adolescent , Child , Child, Preschool , Chronic Disease/epidemiology , Communicable Disease Control/methods , Cross-Sectional Studies , Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage , Female , Hepatitis B Vaccines/administration & dosage , Humans , Immunization Programs/standards , Infant , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Interviews as Topic , Italy/epidemiology , Male , Measles-Mumps-Rubella Vaccine/administration & dosage , Vaccination/standards
4.
Phytochemistry ; 72(14-15): 1786-95, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21708391

ABSTRACT

The present study is aimed at identifying molecular changes elicited by Cr(III) and Cr(VI) on germinating kiwifruit pollen. To address this question, comparative proteomic and DNA laddering analyses were performed. While no genotoxic effect was detected, a number of proteins whose accumulation levels were altered by treatments were identified. In particular, the upregulation of some proteins involved in the scavenging response, cell redox homeostasis and lipid synthesis could be interpreted as an oxidative stress response induced by Cr treatment. The strong reduction of two proteins involved in mitochondrial oxidative phosphorylation and a decline in ATP levels were also observed. The decrease of pollen energy availability could be one of the causes of the severe inhibition of the pollen germination observed upon exposure to both Cr(III) and Cr(VI). Finally, proteomic and biochemical data indicate proteasome impairment: the consequential accumulation of misfolded/damaged proteins could be an important molecular mechanism of Cr(III) toxicity in pollen.


Subject(s)
Actinidia/metabolism , Chromium/pharmacology , Pollen/metabolism , Proteomics/methods , Actinidia/drug effects , Adenosine Triphosphate/analysis , Adenosine Triphosphate/metabolism , DNA Damage/drug effects , DNA, Plant/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , Oxidative Stress/drug effects , Pollen/drug effects , Proteasome Endopeptidase Complex/drug effects , Proteasome Endopeptidase Complex/metabolism , Stress, Physiological/drug effects , Up-Regulation/drug effects
5.
J Econ Entomol ; 104(6): 1793-9, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22299338

ABSTRACT

"Corn stunt" caused by the mollicute Spiroplasma kunkelii (Whitcomb) is potentially one of the most severe diseases affecting the corn (Zea mays L.) crop in the Americas, and the leafhopper Dalbulus maidis (DeLong & Wolcott) is considered its most important vector. However, other insects seen quite frequently in corn crops might well be its vectors in Argentina To identify any leafhoppers species other than D. maidis that can transmit S. kunkelii, transmission assays were conducted, using individuals of Exitianus obscurinervis (Stål) collected in field and reared under controlled conditions. S. kunkelii was transmitted to corn plants by E. obscurinervis. The pathogen was transmitted to seven of the 11 plants, which showed characteristic corn stunt symptoms, and the presence of the pathogen was confirmed by DAS-ELISA. The presence of S. kunkelii in the E. obscurinervis individuals used in transmission experiments was confirmed by polymerase chain reaction and electron microscopy. The current study shows the existence of a new experimental vector of S. kunkelii, the leafhopper E. obscurinervis, which acquired spiroplasmas from infected plants and inoculated it to healthy plants.


Subject(s)
Hemiptera/microbiology , Insect Vectors/microbiology , Plant Diseases/microbiology , Zea mays/microbiology , Animals , Argentina , Enzyme-Linked Immunosorbent Assay , Female , Hemiptera/physiology , Insect Vectors/physiology , Male , Microscopy, Electron , Polymerase Chain Reaction , Spiroplasma/physiology , Zea mays/physiology
6.
Minerva Cardioangiol ; 58(5): 551-65, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20948502

ABSTRACT

AIM: Peripheral arterial disease (PAD) is a chronic figure suitable to be treated at the II stage to prevent the extreme developments both of the critical limb ischemia and the amputation, as well. The aim of this study was to establish a rehabilitation program (pharmacological and physical) focused not only on the improvement of the flow but also on the metabolic rebalancing in the claudicant limb. METHODS: The study enrolled 222 patients, (125 non-diabetics and 97 diabetics): 54 II A and 168 II B stage; 172 patients (131 II B and 41 II A; 104 non-diabetics and 68 diabetics) were submitted to iv. L-propionil carnytine (Lpc) and physical training on treadmill or exercise bike and 50 patients to iv. therapy alone. Instrumental (Rheoscreen, Oximetry, ABI, walking distance measurement) and clinical checks (questionnaire - Appendix 1) were performed at days: T0, T45,T 90,T180, T230 and during the follow up stated at T 90,T180,T360 from T 230 (end of DH). RESULTS: A significant increasing of the walking distance has been reached in the group undergoing the rehabilitation program. Treadmill: non-diabetics +261.48% at 0% and +122.53% at slope 10% (T230) further increasing to +502.31% at 0% and +289.42% at slope 10% (T360); diabetics: + 158.49% at T0 and + 98.26% at slope 10% (T230) further increased to +287.74% at 0% and +197.39% at 10% (T360) in comparison with the group which had only iv. Lpc : non-diabetics +141.63% at 0% and +104.08% at slope 10% (T230) further increased to +202.064% at 0% and +155.10% at slope 10% (T360); diabetics: +109.124% at T0 and +100% at slop 10% (T230) further increased to +171.08% at 0% and +140% at 10% (T360) . Exercise bike: non-diabetics: +170.27% at T230 in comparison T0 increased to +305.4% at T360; diabetics: +166.66 at T230 reaching +288.88% at T 360. CONCLUSION: Our rehabilitative program gives not only good results at the end of the treatment but mainly stable, with the chance to reach further improving of both walking distance and quality of life, particularly in those patients which observe constantly the physical training.


Subject(s)
Peripheral Arterial Disease/rehabilitation , Aged , Cardiotonic Agents/therapeutic use , Carnitine/analogs & derivatives , Carnitine/therapeutic use , Clinical Protocols , Combined Modality Therapy , Diabetes Mellitus, Type 2/complications , Exercise Therapy , Extremities/blood supply , Female , Follow-Up Studies , Humans , Ischemia/complications , Ischemia/rehabilitation , Male , Middle Aged , Peripheral Arterial Disease/drug therapy , Peripheral Arterial Disease/therapy , Regional Blood Flow/physiology , Walking/physiology
7.
Minerva Anestesiol ; 74(6): 329-33, 2008 06.
Article in English | MEDLINE | ID: mdl-18500209

ABSTRACT

Intensive Care Unit (ICU) patients almost uniformly suffer from sleep disruption. Even though the role of sleep disturbances is not still adequately understood, they may be related to metabolic, immune, neurological and respiratory dysfunction and could worsen the quality of life after discharge. A harsh ICU environment, underlying disease, mechanical ventilation, pain and drugs are the main reasons that underlie sleep disruption in the critically ill. Polysomnography is the gold standard in evaluating sleep, but it is not feasible in clinical practice; therefore, other objective (bispectral index score [BIS] and actigraphy) and subjective (nurse and patient assessment) methods have been proposed, but their adequacy in ICU patients is not clear. Frequent evaluation of neurological status with validated tools is necessary to avoid excessive or prolonged sedation in order to better titrate patient-focused therapy. Hypnotic agents like benzodiazepines can increase total sleep time, but they alter the physiological progression of sleep phases, and decrease the time spent in the most restorative phases compared to the phases normally mediated by melatonin; melatonin production is decreased in critically ill patients, and as such, exogenous melatonin supplementation may improve sleep quality. Sleep disruption and the development of delirium are frequently related, both because of sleep scarcity and inappropriate dosing with sedatives. Delirium is strongly related to increased ICU morbidity and mortality, thus the resolution of sleep disruption could significantly contribute to improved ICU outcomes. An early evaluation of delirium is strongly recommended because of the potential to resolve the underlying causes or to begin an appropriate therapy. Further studies are needed on the effects of strategies to promote sleep and on the evaluation of better sleep in clinical outcomes, particularly on the development of delirium.


Subject(s)
Delirium , Intensive Care Units , Sleep Wake Disorders , Critical Illness , Delirium/etiology , Delirium/prevention & control , Humans , Sleep Wake Disorders/etiology , Sleep Wake Disorders/prevention & control
8.
Dig Liver Dis ; 38(8): 563-77, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16807150

ABSTRACT

BACKGROUND AND AIM: Kupffer cells are intrasinusoidal space located macrophages with phagocytic capacity. Interferons are cytokines with antiviral, antiproliferative and immunomodulatory activities which may influence the activity of Kupffer cells. Aim of this study was to evaluate Kupffer cell gene expression after interferon-alpha or interferon-gamma stimulation in order to investigate a link between these cytokines and macrophage activation. METHODS: Rat Kupffer cells were cultured for 24 h and divided into three groups: unstimulated; stimulated with interferon-alpha and stimulated with interferon-gamma. After 8 h stimulation total RNA was extracted and processed according to Affymetrix protocols and hybridised on R34A microarray gene set. Data analyses was performed using Microarray Analysis Suite 5.0 software. Genes showing remarkably different expression in microarray analysis were confirmed by real-time PCR. RESULTS: Nearly 4000 out of the 8800 genes represented in the array were expressed by Kupffer cells. Among these, interferon-alpha up-regulates 91 genes by over two-fold (antiviral, antigen processing and presentation, and tumour suppressor/proapoptotic genes) and down-regulates 72 genes by 50% or more. Interferon-gamma up-regulates 70 genes by over two-fold and down-regulates 78 genes by 50% or more. Most of the genes induced by interferon-alpha are also induced by interferon-gamma. Down-regulated genes include growth factors and genes involved in cell cycle/proliferation. Real-time PCR confirms the results of the array. CONCLUSION: Interferons directly target rat Kupffer cells and are involved in the regulation of a wide variety of genes. Their expression profile shed light onto molecular mechanism of Kupffer cells activation in specific pathways such as antiviral and antitumour processes.


Subject(s)
Antiviral Agents/pharmacology , Gene Expression Profiling , Immunologic Factors/pharmacology , Interferon-alpha/pharmacology , Interferon-gamma/pharmacology , Kupffer Cells/drug effects , Animals , Apoptosis/drug effects , Apoptosis/genetics , Cell Cycle/drug effects , Cell Cycle/genetics , Cell Proliferation/drug effects , Cells, Cultured , Cytokines/drug effects , Cytokines/genetics , Down-Regulation/drug effects , Female , Genes, Tumor Suppressor/drug effects , Immunity, Cellular/drug effects , Immunity, Cellular/genetics , Immunologic Factors/genetics , Macrophage Activation/drug effects , Macrophage Activation/genetics , Oligonucleotide Array Sequence Analysis , Phagocytosis/drug effects , Phagocytosis/genetics , RNA, Messenger/drug effects , RNA, Messenger/genetics , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Signal Transduction/genetics , Transcription Factors/drug effects , Transcription Factors/genetics , Up-Regulation/drug effects
10.
Eur Rev Med Pharmacol Sci ; 9(6): 373-8, 2005.
Article in English | MEDLINE | ID: mdl-16479743

ABSTRACT

Polymyalgia rheumatica (PMR) is a chronic inflammatory condition of the elderly, characterized by aching and morning stiffness in the cervical region, shoulders and pelvic girdles. A steroid treatment course of 6-24 months is often required, but, due to important side effects, it is troublesome if the PMR patient is also affected by diabetes mellitus (DM) and/or osteoporosis. Aim of our study is to test anti-TNF alpha treatment as a steroid sparing tool in PMR patients affected by DM or osteoporosis. In particular, we hypothesise that TNF alpha blockade can be useful not only in remission maintaining, but also in the induction of clinical remission without corticosteroids in this kind of patients. In a six months follow up, patients had clinical improvement, confirmed by physical medical examination, and a statistically significant reduction in ESR and CRP mean values. Anti-TNF alpha treatment was well tolerated by all patients. These preliminary data suggest than Infliximab can be useful in the treatment of PMR patients, not only for steroid sparing purposes, but also as first line therapy in PMR patients with severe comorbidity, such as diabetes mellitus or osteoporosis.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 2/complications , Osteoporosis/complications , Polymyalgia Rheumatica/drug therapy , Tumor Necrosis Factor-alpha/immunology , Aged , Aged, 80 and over , Antirheumatic Agents/therapeutic use , Female , Humans , Infliximab , Polymyalgia Rheumatica/complications , Remission Induction , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors
11.
Dig Liver Dis ; 36(6): 423-5, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15248384

ABSTRACT

Infliximab has been proven to be an effective therapy in a miscellany of rheumatic diseases and has been approved for the treatment of moderate-to-severe Crohn's disease with an inadequate response to conventional therapy and for the management of enterocutaneous fistulas. Data about the role of infliximab in ulcerative colitis are still controversial. Here, we report a case of a patient with sacroileitis and peripheral arthropathy associated with left-sided ulcerative colitis who achieved a sustained clinical remission after infliximab therapy.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Colitis, Ulcerative/complications , Colitis, Ulcerative/drug therapy , Gastrointestinal Agents/therapeutic use , Sacroiliac Joint , Synovitis/drug therapy , Adult , Female , Humans , Infliximab , Synovitis/etiology
14.
Aliment Pharmacol Ther ; 18(6): 627-33, 2003 Sep 15.
Article in English | MEDLINE | ID: mdl-12969089

ABSTRACT

BACKGROUND: Levofloxacin has been shown to be effective in Helicobacter pylori eradication. Two 10-day levofloxacin-based triple therapies were compared with standard 7- and 14-day quadruple regimens in second-line treatment. METHODS: Two hundred and eighty consecutive patients who failed to respond to standard triple therapy (clarithromycin, amoxicillin, rabeprazole) were randomly assigned to four groups: (1) levofloxacin 500 mg o.d., amoxicillin 1 g b.d., rabeprazole 20 mg b.d. for 10 days (LAR, n = 70); (2) levofloxacin 500 mg o.d., tinidazole 500 mg b.d., rabeprazole 20 mg b.d. for 10 days (LTR, n = 70); (3) tetracycline 500 mg q.d.s., metronidazole 500 mg t.d.s., bismuth salt 120 mg q.d.s., rabeprazole 20 mg b.d. for 7 days (7TMBR, n = 70); and (4) for 14 days (14TMBR, n = 70). Helicobacter pylori status and side-effects were assessed 6 weeks after treatment. RESULTS: The eradication rate was 94% in the LAR group and 90% in the LTR group in both intention-to-treat and per protocol analyses. Helicobacter pylori eradication was achieved in 63 and 69% of the 7TMBR group and in 69 and 80% of the 14TMBR group in intention-to-treat and per protocol analysis, respectively. Side-effects were significantly lower in the LAR and LTR groups than in the 14TMBR group. CONCLUSION: Ten-day levofloxacin-based therapies are better than standard quadruple regimens as second-line option for H. pylori eradication.


Subject(s)
Anti-Infective Agents/administration & dosage , Drug Therapy, Combination/administration & dosage , Helicobacter Infections/drug therapy , Helicobacter pylori , Levofloxacin , Ofloxacin/administration & dosage , Adolescent , Adult , Aged , Antacids/administration & dosage , Antacids/adverse effects , Anti-Infective Agents/adverse effects , Bismuth/administration & dosage , Bismuth/adverse effects , Drug Therapy, Combination/adverse effects , Female , Humans , Male , Middle Aged , Ofloxacin/adverse effects , Patient Compliance , Prospective Studies , Treatment Outcome
15.
Aliment Pharmacol Ther ; 16 Suppl 2: 145-57, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11966535

ABSTRACT

BACKGROUND: H. pylori infection is a major risk factor in gastric cancer development. The availability of cDNA microarrays creates the unprecedented opportunity to examine simultaneously dynamic changes of multiple pathways affected by H. pylori infection. AIM: In this study we examined broad patterns of gene expression induced by H. pylori in the gastric cancer cell line 1739-CRL AGS cells in culture using the U95A microarray. METHODS: H. pylori were cocultured with AGS cells for 4, 12, 24 and 48 h. Total RNA was extracted and after labelling was used for detection of genes represented in the human U95A microarray set. Data analyses were performed using GeneChip and CLUSFAVOR software. RESULTS: Nearly 6000 genes present in the array were expressed by AGS cells. We report approximately 200 genes that showed the most marked changes. Our studies confirm the up-regulation of c-jun, jun-B, c-fos and cyclin D1 by H. pylori. We report for the first time the induction of the serine threonine kinase pim-1 and ATF3 by H. pylori infection of AGS cells. CONCLUSIONS: In this microarray analysis of gene expression induced by H. pylori in gastric epithelial cells, we identified a large number of unsuspected genes affected by H. pylori. Further, we show that unsupervised hierarchical cluster analysis can provide useful insight into the possible contribution of genes in specific pathways, based on their profile of expression.


Subject(s)
Gene Expression Profiling , Helicobacter Infections/genetics , Helicobacter pylori/isolation & purification , Stomach Neoplasms/genetics , Activating Transcription Factor 3 , Epithelial Cells , Helicobacter Infections/metabolism , Humans , Multigene Family/genetics , Oligonucleotide Array Sequence Analysis , Protein Serine-Threonine Kinases/genetics , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-pim-1 , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , Transcription Factors/genetics , Tumor Cells, Cultured , Up-Regulation
17.
Panminerva Med ; 42(1): 55-9, 2000 Mar.
Article in English | MEDLINE | ID: mdl-11019606

ABSTRACT

Sucralfate is a cytoprotective drug widely used in clinical practice to prevent or treat several gastrointestinal diseases such as gastro-esophageal reflux, gastritis, peptic ulcer, stress ulcer and dyspepsia. Sucralfate is a safe and well tolerated drug, as demonstrated by the quite complete lack of side effects and it is, for this reason, one of the most important therapeutic choices in the management of acid related diseases during pregnancy. Moreover, sucralfate has recently been shown to be useful in non-acid related gastrointestinal disease as well. In fact, sucralfate has also been administered topically in patients with radiation-induced mucosal procto-sigmoiditis or ulcerative colitis with surprising results. The drug is actually able to form a physical barrier between epithelium and damaging agents (-bile salts, drugs, refluxate...). Moreover, sucralfate increases the local levels of fibroblast growth factors and induces a rise in the mucosal concentration of prostaglandins which are considered important factors in mucosal healing. The aim of this paper is to describe the current and probably forthcoming uses of sucralfate in the field of gastrointestinal disorders. Moreover, we investigate the role of sucralfate as a reliable means to prevent the occurrence of reflux-like symptoms after Helicobacter pylori eradication and in the management of Helicobacter pylori negative patients affected by non-ulcer dyspepsia.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Gastrointestinal Agents/therapeutic use , Gastrointestinal Diseases/drug therapy , Sucralfate/therapeutic use , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...